


Biohit Oyj Email Formats
Biotechnology Research • Helsinki, Uusimaa, Finland • 51-100 Employees
Biohit Oyj Email Formats
Biohit Oyj uses 5 email formats. The most common is {first initial}.{last name} (e.g., j.doe@biohit.fi), used 58.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@biohit.fi | 58.6% |
{first name}.{last name} | john.doe@biohit.fi | 27.6% |
{first name} | john@biohit.fi | 6.9% |
{first initial} | j@biohit.fi | 3.4% |
{first initial}.{second initial} | j.o@biohit.fi | 3.4% |
Key Contacts at Biohit Oyj
Jussi Hahtela
Ceo
Daniela Söderström
Quality And Regulatory Affairs Director
Suvi Elomaa
Production Director
Tapani Tiusanen
Cto, Director Operations & Ict
Päivi Lipponen
Sales Director
Robert Gearty
Managing Director
Company overview
| Headquarters | Laippatie 1, Helsinki, Southern Finland 00880, FI |
| Phone number | +3589773861 |
| Website | |
| NAICS | 541714 |
| Keywords | Acetium, Gastro Panel, Quick Tests |
| Founded | 1988 |
| Employees | 51-100 |
| Socials |
About Biohit Oyj
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com Product range consists of products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. Acetium innovation is developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. We are looking for distributors and licencing partners.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Biohit Oyj has 24 employees across 10 departments.
Departments
Number of employees
Funding Data
Biohit Oyj has never raised funding before.
Biohit Oyj Tech Stack
Discover the technologies and tools that power Biohit Oyj's digital infrastructure, from frameworks to analytics platforms.
Marketing automation
Frequently asked questions
4.8
40,000 users



